AstraZeneca
-
AstraZeneca invests USD18.5B in China partnership to enter the obesity drug market
CSPC is expected to receive an additional USD3.5 billion if the programs successfully meet development and regulatory milestones, in addition to royalties from any drugs approved under the partnership.
-
AstraZeneca commits USD15B to China expansion through 2030 as Starmer visits Beijing
The investment will enhance AstraZeneca’s existing manufacturing sites in Wuxi, Beijing, Qingdao, and Taizhou, which already serve patients in China and across 70 international markets.
-
China approves Daiichi Sankyo/AstraZeneca’s Enhertu for advanced gastric cancer
The approval specifically targets patients who have already undergone one prior trastuzumab-based treatment regimen.
-
AstraZeneca acquires full rights to liver cancer therapy in USD630M deal with AbelZeta
AbelZeta will receive up to USD630 million from AstraZeneca, with the payment structure including both upfront cash and milestone fees tied to the GPC3 program’s progress in China.
-
MoPH signs MoU with AstraZeneca to strengthen lung cancer care in Lebanon
This initiative aligns with the Ministry’s National Cancer Plan 2023–2028 and represents a key step in advancing Lebanon’s cancer control strategy.
-
AstraZeneca commits USD2B to expand Maryland manufacturing operations
The new facility will produce molecules for medical trials. These expansions will create 200 additional jobs in Frederick and 100 more in Gaithersburg.